Evidence map›Paper›PMID 39694787›Full record

Trial reportAcademic radiology2025

HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression.

Isabella M Kimbel, Veronica Wallaengen, Evangelia I Zacharaki, Adrian L Breto, Ahmad Algohary, Sophia Carbohn, Sandra M Gaston, Nachiketh Soodana-Prakash, Pedro F S Freitas, Oleksandr N Kryvenko and 9 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Academic radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02242773 (MRI-Guided Active Selection for Treatment of Prostate Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02242773 nacompletednot on this map

MRI-Guided Active Selection for Treatment of Prostate Cancer: The Miami MAST Trial

TypeinterventionalSponsorUniversity of MiamiRan2014 to 2024Enrolled208ConditionsProstate CancerArmsMulti-Parametric MRI, MRI-Guided Biopsy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Isabella M KimbelDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.).
Veronica WallaengenDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.); Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.).
Evangelia I ZacharakiDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.).
Adrian L BretoDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.).
Ahmad AlgoharyDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.).
Sophia CarbohnDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.).
Sandra M GastonDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Nachiketh Soodana-PrakashDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.).
Pedro F S FreitasDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.).
Oleksandr N KryvenkoSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.); Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA (O.N.K.).
Patricia CastilloDepartment of Radiology, University of Miami Miller School of Medicine, Miami, Florida, USA (P.C.).
Matthew C AbramowitzDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Chad R RitchDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Bruno NaharDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Mark L GonzalgoDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Dipen J ParekhDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Alan PollackDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Sanoj PunnenDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA (V.W., N.S.-P., P.F.S.F., C.R.R., B.N., M.L.G., D.J.P., S.P.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.).
Radka StoyanovaDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA (I.M.K., V.W., E.I.Z., A.L.B., A.A., S.C., S.M.G., M.C.A., A.P., R.S.); Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA (S.M.G., O.N.K., M.C.A., C.R.R., B.N., M.L.G., D.J.P., A.P., S.P., R.S.). Electronic address: rstoyanova@med.miami.edu.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate CancerU01CA239141 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI POLLACK, ALAN, PUNNEN, SANOJ · 2019 to 2023
$3.0M
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer AggressivenessU01CA271400 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SANDRA M GASTON, Alan Pollack · 2022 to 2026
$1.7M
NCI NIH HHS K12 CA226330NCI NIH HHS P30 CA240139NCI NIH HHS U01 CA239141NCI NIH HHS U01 CA271400
6 · The paper itself

Abstract

RATIONALE AND

objectivesActive surveillance (AS) is the preferred management strategy for low-risk prostate cancer. This study aimed to evaluate the impact of Habitat Risk Score (HRS), an automated approach for mpMRI analysis, for early detection of progressors in a prospective AS clinical trial (MAST NCT02242773). MATERIALS AND

methodsThe MAST protocol includes Confirmatory mpMRI ultrasound fusion (MRI-US) biopsy and yearly surveillance MRI-US biopsies for up to 3 years. Clinical and mpMRI data from patients that progressed based on protocol criteria at years 1-3 were reviewed. Patients were classified as "MRI/HRS Progressors" if the PI-RADS lesion(s) had been targeted throughout the surveillance and resulted in positive biopsies, or as "Missed Progressors" if the lesion(s) were not identified by PI-RADS ("PI-RADS Miss") or were missed by the biopsy ("Needle Miss"). HRS maps were generated for each patient and evaluated for association with histopathological progression.

resultsOf the 34 patients, 15 were classified as "MRI/HRS Progressors" and 19 as "Missed Progressors" (12 "PI-RADS Miss", seven "Needle Miss"). In all cases, HRS confirmed the PI-RADS assessment. In the "PI-RADS Miss" group, HRS identified the lesions in all patients that were not targeted by biopsy and resulted in patient reclassification. HRS volumes showed clear association with tumor evolution both in terms of volume and aggressiveness over time.

conclusionHRS volumes can serve as a quantitative biomarker for early detection of progression and lead to timely conversion to treatment, thereby improving patient outcomes and reducing the burden of unnecessary surveillance.

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsWatchful WaitingAgedDisease ProgressionHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleMiddle AgedMultimodal ImagingProspective StudiesRisk AssessmentUltrasonographyActive surveillanceHabitat imagingMpMRIProgressionProstate cancer

Identifiers

PMID39694787
PMCPMC11981859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.